20820 Federal Register / Vol. 66, No. 80 / Wednesday, April 25, 2001 / Notices

toward the elimination of health

disparities in the U.S. The OMWH

proposes to conduct a survey for the

purpose of obtaining baseline data on

the racial, ethnic, and gender

composition of both users and staff at its

supported programs.

Numerous studies have shown that

women and people of diverse racial and

ethnic background are more comfortable

seeking and receiving health care from

providers of their same gender, race,

and ethnic background. These studies

suggest that women and people of

diverse race/ethnicity perceive that their

health care is more attuned to their

unique health and psychosocial

circumstances when diverse providers

are available to them. A diverse

workforce in BPHC supported programs

may contribute significantly to the

reduction of a significant psychological

barrier to health care for many women

and people of color.

The burden estimate for this project is

as follows:

Form Number of

respondents

Responses per

respondent Total responses Hours perresponse

Total hour

burden

Center Directors ............................................... 150 1 150 .25 38

Center Staff ...................................................... 1 150 28 4200 .08 336

Total ...................................................... ............................ ............................ 4350 ............................ 374

1Sites.

Send comments to Susan G. Queen,

Ph.D., HRSA Reports Clearance Officer,

Room 14–33, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857.

Written comments should be received

within 60 days of this notice.

Dated: April 17, 2001.

James J. Corrigan,

Associate Administrator for Management and

Program Support.

[FR Doc. 01–10228 Filed 4–24–01; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

HRSA AIDS Advisory Committee;

Notice of Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee

Act(Pub. L. 92–463), announcement is

made of the following National

Advisory body scheduled to meet

during the month of June 2001.

Name: HRSA AIDS Advisory Committee

(HAAC).

Date and Time: June 4, 2001; 8:30 a.m.—

5 p.m.

Place: Centers for Disease Control and

Prevention; Corporate Square; Corporate

Blvd., Building 8, first floor; Atlanta, Georgia

30329; Telephone: (404) 639–8008.

Date and Time: June 5, 2001; 8:30 a.m.—

3:30 p.m.

Place: Outreach, Inc.; 825 Cascade Ave.,

SW; Atlanta, GA 30311; Telephone: (404)

755–6700.

The meeting is open to the public.

Agenda: Agenda items for the meeting

include a discussion of HIV prevention and

care linkages with the Centers for Disease

Control and Prevention’s Advisory

Committee on HIV and STD Prevention and

rural issues.

Anyone requiring further information

should contact Joan Holloway, HIV/AIDS

Bureau, Parklawn Building, Room 7–13, 5600

Fishers Lane, Rockville, Maryland 20857,

Telephone (301) 443–5761.

Dated: April 18, 2001.

Jane Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 01–10229 Filed 4–24–01; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Proposed Collection;

Comment Request; Multi-Ethnic Study

of Atherosclerosis (MESA) Event

Surveillance

SUMMARY: In compliance with the

requirement of section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995,

for opportunity for public comment on

proposed data collection projects, the

National Heart, Lung, and Blood

Institute (NHLBI), the National

Institutes of Health (NIH) will publish

periodic summaries of proposed

projects to be submitted to the Office of

Management and Budget (OMB) for

review and approval.

Proposed Collection

Title: Multi-Ethnic Study of

Atherosclerosis (MESA) Event

Surveillance. Type of Information

Request: New. Need and Use of

Information Collection: The study,

MESA, will identify and quantify factors

associated with the presence and

progression of subclinical

cardiovascular disease (CVD)—that is,

atherosclerosis and other forms of CVD

that have not produced signs and

symptoms. The findings will provide

important information on subclinical

CVD in individuals of different ethnic

backgrounds and provide information

for studies on new interventions to

prevent CVD. The aspects of the study

that concern direct participant

evaluation received a clinical exemption

from OMB clearance (CE–99–11–08) in

April 2000. OMB clearance is being

sought for the contact of physicians and

participant proxies to obtain

information about clinical CVD events

that participants experience during the

follow-up period. Frequency of

response: Once per CVD-event. Affected

public: Individuals. Types of

Respondents: Physicians and selected

proxies of individuals recruited for

MESA. The annual reporting burden is

as follows: Estimated Number of

Respondents: 555; Estimated Number of

Responses per respondent: 1.0; and

Estimated Total Annual Burden Hours

Requested: 42.

There are no capital, operating, or

maintenance costs to report.

Type of respondents

Estimated

number of

respondents

Estimated

number of

responses per

respondent

Average burden hours

per response

Estimated total

annual burden

hours requested

Physicians ................................................................................ 279 1.0 0.20 19

Particpant proxies .................................................................... 276 1.0 0.25 23

Total .................................................................................. 555 1.0 0.225 42

Federal Register / Vol. 66, No. 80 / Wednesday, April 25, 2001 / Notices 20821

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information will

have practical utility; (2) the accuracy of

the agency’s estimate of burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) ways to minimize the

burden of collection of information on

those who are to respond, including the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

data collection plans and instruments,

contact Dr. Diane Bild, Epidemiology

and Biometry Program, Division of

Epidemiology and Clinical

Applications, NHLBI, NIH, II Rockledge

Centre, 6701 Rockledge Drive, MSC

#7934, Bethesda, MD 20892–7934, or

call non-toll-free number (301) 435–

0457, or e-mail your request, including

your address to: bd3@nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

June 25, 2001.

Dated: April 13, 2001.

Peter J. Savage,

Acting Director, Division of Epidemiology and

Clinical Applications, National Heart, Lung,

and Blood Institute.

[FR Doc. 01–10205 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Molecular

Target Drug Discovery for Cancer.

Date: April 18, 2001.

Time: 12:30 p.m. to 1:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Cancer Institute, 6116

Executive Boulevard, Conference Room 8052,

Rockville, MD 20852 (Telephone Conference

Call).

Contact Person: Joyce C. Pegues, Ph.D.,

Scientific Review Administrator, Special

Review, Referral, and Resources Branch,

Division of Extramural Activities, National

Cancer Institute, 6116 Executive Boulevard,

Room 8084, Bethesda, MD 20892, 301/594–

1286.

This notice is being published less than 15

days prior to the meeting due to scheduling

conflicts. Any interested person may file

written comments with the committee by

forwarding the statement to the Contact

Person listed on this notice. The statement

should include the name, address, telephone

number and when applicable, the business or

professional affiliation of the interested

person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: April 17, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–10204 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Sickle Cell Disease Advisory

Committee.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Sickle Cell Disease

Advisory Committee.

Date: June 4, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: Discussion of program policies

and issues.

Place: National Institutes of Health, Two

Rockledge Center, Conference Room 9112,

9116, 6701 Rockledge Drive, Bethesda, MD

20892.

Contact Person: Charles M. Peterson, MD,

Director, Blood Diseases Program, Division of

Blood Diseases and Resources, National

Heart, Lung, and Blood Institute, NIH, Two

Rockledge Center, Room 10158, MSC 7950,

6701 Rockledge Drive, Bethesda, MD 20892,

301/435–0050.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: April 18, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–10198 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date: April 24, 2001.

Time: 7:30 a.m. to 9:30 am.

Agenda: To review and evaluate grant

applications.

Place: 6000 Executive Blvd., Rm. 409,

Rockville, MD 20892, (Telephone Conference

Call).

Contact Person: Sean O’Rourke, Scientific

Review Administrator, Extramural Project

Review Branch, National Institute on Alcohol